CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $10.46B, above the global median of $1.15B
- PositionOperating margin is 46.1%, higher than 95% of its Biotechnology peers (median -34.2%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.46BUSDvs all stocks (USD)
Trailing P/E
47.38xvs Biotechnology peers
Revenue (TTM)
417.30MUSDvs all stocks (USD)
Profit Margin
53.92%vs Biotechnology peers
Beta
0.4970xvs all stocks
52-Week Change
139.62%vs all stocks
Market Capitalization
10.46BUSDvs all stocks (USD)
Enterprise Value
9.65BUSDvs all stocks (USD)
Trailing P/E
47.38xvs Biotechnology peers
Forward P/E
35.44xvs Biotechnology peers
PEG Ratio
0.8768xvs Biotechnology peers
Price to Sales (TTM)
25.07xvs Biotechnology peers
Price to Book (MRQ)
8.18xvs Biotechnology peers
Enterprise to Revenue
23.12xvs Biotechnology peers
Enterprise to EBITDA
53.45xvs Biotechnology peers
Gross Margin
94.57%vs Biotechnology peers
Profit Margin
53.92%vs Biotechnology peers
Operating Margin
46.14%vs Biotechnology peers
Return on Assets (TTM)
9.04%vs Biotechnology peers
Return on Equity (TTM)
19.90%vs Biotechnology peers
Revenue (TTM)
417.30MUSDvs all stocks (USD)
Revenue per Share (TTM)
14.36USDUpdated Jul 19, 2026Quarterly Revenue Growth
31.90%vs Biotechnology peers
Gross Profit (TTM)
392.96MUSDvs all stocks (USD)
EBITDA (TTM)
185.28MUSDvs all stocks (USD)
Net Income (TTM)
225.03MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
56.50%vs Biotechnology peers
Operating Cash Flow (TTM)
250.28MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
137.49MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
389.13MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
23.05MUSDFY2025 · Dec 31, 2025Gross Profit
366.08MUSDFY2025 · Dec 31, 2025Operating Income
161.29MUSDvs all stocks (USD)
Pre-tax Income
189.47MUSDFY2025 · Dec 31, 2025Income Tax Expense
-15.36MUSDFY2025 · Dec 31, 2025Net Income
204.83MUSDFY2025 · Dec 31, 2025EBIT
161.29MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
167.85MUSDFY2025 · Dec 31, 2025Research & Development
58.05MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
146.74MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
28.18MUSDFY2025 · Dec 31, 2025EPS (Basic)
7.08USDFY2025 · Dec 31, 2025EPS (Diluted)
6.84USDFY2025 · Dec 31, 2025Basic Shares Outstanding
28.94MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
28.94MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
204.83MUSDFY2025 · Dec 31, 2025Operating Cash Flow
217.85MUSDFY2025 · Dec 31, 2025Free Cash Flow
205.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
496.30MUSDFY2025 · Dec 31, 2025Income Tax Paid
15.67MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
204.83MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.55MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-22.84MUSDFY2025 · Dec 31, 2025Stock-based Compensation
54.51MUSDFY2025 · Dec 31, 2025Other Non-cash Items
684.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.12MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
826.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.58MUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.95MUSDFY2025 · Dec 31, 2025Purchase of Investments
-422.54MUSDFY2025 · Dec 31, 2025Sale of Investments
375.64MUSDFY2025 · Dec 31, 2025Other Investing Activity
435.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-58.42MUSDFY2025 · Dec 31, 2025Other Financing Charges
-13.96MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.96MUSDFY2025 · Dec 31, 2025Shares Outstanding
29.44MSharesUpdated Jul 19, 2026Float Shares
23.42MSharesUpdated Jul 19, 2026Shares Short
3.52MSharesUpdated Jul 19, 2026Short Ratio
9.04daysvs all stocks
Short % of Shares Outstanding
19.59%vs all stocks
% Held by Insiders
10.97%vs all stocks
% Held by Institutions
99.57%vs all stocks
Total Cash (MRQ)
823.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
27.93USDUpdated Jul 19, 2026Total Debt (MRQ)
9.11MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0071xvs Biotechnology peers
Current Ratio (MRQ)
9.46xvs Biotechnology peers
Book Value per Share (MRQ)
43.37USDUpdated Jul 19, 2026Total Assets
1.33BUSDvs all stocks (USD)
Total Current Assets
1.02BUSDFY2025 · Dec 31, 2025Total Liabilities
114.23MUSDFY2025 · Dec 31, 2025Total Non-current Assets
309.19MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
11.29MUSDFY2025 · Dec 31, 2025Total Current Liabilities
102.94MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
496.30MUSDFY2025 · Dec 31, 2025Other Short-term Investments
331.49MUSDFY2025 · Dec 31, 2025Accounts Receivable
127.42MUSDFY2025 · Dec 31, 2025Inventory
40.48MUSDFY2025 · Dec 31, 2025Accounts Payable
3.24MUSDFY2025 · Dec 31, 2025Short-term Debt
1.77MUSDFY2025 · Dec 31, 2025Other Current Liabilities
3.58MUSDFY2025 · Dec 31, 2025Long-term Debt
7.57MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.72MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
24.16MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.22BUSDvs all stocks (USD)
52-Week Low
130.50USDUpdated Jul 19, 202652-Week High
382.54USDUpdated Jul 19, 202652-Week Change
139.62%vs all stocks
Beta
0.4970xvs all stocks
50-Day MA
328.76USDUpdated Jul 19, 2026200-Day MA
263.77USDUpdated Jul 19, 2026Avg 10-Day Volume
352.21KSharesUpdated Jul 19, 2026Avg 30-Day Volume
379.08KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
7.49USDUpdated Jul 19, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Where is this company structurally exposed?
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 46.1%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.46Industry median: -0.34Industry P95: 0.41Peers compared: 261
Profit margin is 53.9%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.54Industry median: -0.46Industry P95: 0.43Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $10.46B, above the global median of $1.15BNotable
Market cap (USD): 10,461,185,919Global Median: 1,146,734,693.424
Levered free cash flow is $137.49M, above the global median of $16.24MNotable
Levered free cash flow (USD): 137,491,504Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Globus Medical Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Global Ship Lease Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Exelixis Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
United States Lime & Minerals Inc.
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels